Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex

European Journal of Pharmaceutical Sciences

Volumn 9, Issue 2, 1999, Pages 163-170

  Berton, Myriam ^a   Allémann, Eric ^a   Stein, Cy A ^b   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

Antisense oligonucleotide; Biodegradable polymer; Drug delivery; HIV 1; Nanoparticle; Poly (D,L lactic acid)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CETRIMIDE; MEDISORB 100DL; NANOPARTICLE; POLYLACTIC ACID; POLYMER; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DISPERSION; DRUG DELIVERY SYSTEM; EMULSION; ENCAPSULATION; GENE TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS 1; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

CETRIMONIUM COMPOUNDS; DIFFUSION; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; PHOSPHOROUS ACIDS; POLYMERS; SOLUBILITY;

EID: 0343415618     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(99)00049-4     Document Type: Article

References (37)

1. Akhtar S., Lewis J.K. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int. J. Pharm. 157:1997;57-67.
2. Akhtar S., Rossi J.J. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? J. Antimicrob. Chemother. 38:1996;159-165.
3. Allémann E., Doelker E., Gurny R. Drug loaded poly(lactic acid) nanoparticles produced by a reversible salting-out process: purification of an injectable dosage form. Eur. J. Pharm. Biopharm. 39:1993;13-18.
4. Benimetskaya L., Takle G., Vilenchik M., Lebedeva I., Miller P., Stein C.A. Cellular delivery of antisense oligodeoxynucleotides by a novel cationic porphyrin vehicle. Nucleic Acids Res. 26:1998;5310-5317.
5. Bennett C.F. Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol. 55:1998;9-19.
6. Bennett C.F., Mirejovsky D., Crooke R.M., Tsai Y.J., Felgner J., Sridhar C.N., et al. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. J. Drug Targ. 5:1998;149-162.
7. Berton M., Benimetskaya L., Allémann E., Stein C.A., Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur. J. Pharm. Biopharm. Eur. J. Pharm. Biopharm. 47:1999;119-123.
8. Berton M., Sixou S., Kravtzoff R., Dartigues C., Imbertie L., Allal C., et al. Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular BioVector (SMBV). Biochim. Biophys. Acta. 1355:1997;7-19.
9. Cazenave C., Stein C.A., Loreau N., Thuong N.T., Neckers L.M., Subasinghe C., et al. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 17:1989;4255-4273.
10. Chavany C., Le doan T., Couvreur P., Puisieux F., Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm. Res. 9:1992;441-449.
11. Chavany C., Saison-Behmoaras T., Le doan T., Puisieux F., Couvreur P., Helene C. Adsorption of oligonucleotides onto polyisohexylcyanoyacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11:1994;1370-1378.
12. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery systems for proteins based on poly (lactic/glycolic acid) microspheres. Pharm. Res. 8:1991;713-720.
13. Crooke S.T. Delivery of oligonucleotides and polynucleotides. J. Drug Targ. 3:1995;185-190.
14. Delong R., Stephenson K., Loftus T., Fisher M., Alahari S., Nolting A., Juliano R.L. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86:1997;762-764.
15. Fattal E., Vauthier C., Aynie I., Nakada Y., Lambert G., Malvy C., Couvreur P. Biodegradable polyalkycyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Control. Rel. 53:1998;137-143.
16. Hélène C., Toulme J.J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta. 1049:1990;99-125.
17. Hughes J.A., Aronsohn A.I., Avrutskaya A.V., Juliano R.L. Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Pharm. Res. 13:1996;404-410.
18. Leroux J.C., Allémann E., Doelker E., Gurny R. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur. J. Pharm. Biopharm. 41:1995;14-18.
19. Lewis J.G., Lin K.Y., Kothavale A., Flanagan W.M., Matteucci M.D., Deprince R.B., et al. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA. 93:1996;3176-3181.
20. Lewis J.K., Irwin W.J., Akhtar S. Biodegradable poly(L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. J. Control. Rel. 37:1995;173-183.
21. Liu L.S., Kost J., D'Emuanuelle L.R. Experimental approach to elucidate the mechanism of ultrasound-enhanced polymer erosion and release of incorporated substances. Macromol. 25:1992;123-128.
22. Lourenco C., Teixeira M., Simões S., Gaspar R. Steric stabilization of nanoparticles: size and surface properties. Int. J. Pharm. 138:1996;1-12.
23. Mahato R.I., Rolland A., Tomlison E. Cationic lipid-based gene delivery systems: pharmaceutical perspectives. Pharm. Res. 14:1997;853-859.
24. Nakanishi M., Mizuguchia H., Ashihara K., Senda T., Akuta T., Okabe J., et al. Gene transfer vectors based on Sendai virus. J. Control. Rel. 54:1998;61-68.
25. Narayanan R., Akhtar S. Antisense therapy. Curr. Opin. Oncol. 8:1996;509-515.
26. Oliveira M.C., Fattal E., Ropert C., Malvy C., Couvreur P. Delivery of antisense oligonucleotides by means of pH-sensitive liposomes. J. Control. Rel. 48:1997;179-184.
27. Reich G. Ultrasound-induced degradation of PLA and PLGA during microsphere processing: influence of formulation variables. Eur. J. Pharm. Biopharm. 45:1998;165-171.
28. Shaw D.R., Rustagi P.K., Kandimalla E.R., Manning A.N., Jiang Z., Agrawal S. Effects of synthetic oligonucleotides on human complement and coagulation. Biochem. Pharmacol. 53:1997;1123-1132.
29. Stein C.A. Does antisense exist? Nature Medicine. 1:1995;1119-1121.
30. Stein C.A. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol. 14:1996;147-149.
31. Stein C.A., Krieg A.M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4:1994;67-69.
32. Waelti E.R., Glück R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Pharm. 77:1998;728-733.
33. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 75:1978;280-284.
34. Zelphati O., Imbach J.L., Signoret N., Zon G., Rayner B., Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 22:1994;4307-4314.
35. Zelphati O., Szoka F.C. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 13:1996;1367-1372.
36. Zelphati O., Szoka F.C. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet? J. Control. Rel. 41:1996;99-119.
37. Zelphati O., Szoka F.C. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA. 93:1996;11493-11498.